Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy

Launched by ZHUJIANG HOSPITAL · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at the gut bacteria of patients with a condition called Monoclonal Gammopathy of Undetermined Significance (MGUS). MGUS is when there are abnormal proteins in the blood, but it is not yet clear what it means for the patient's health. Researchers want to understand if the bacteria in the gut play a role in this condition. To do this, they will collect blood and stool samples from people with MGUS, those with similar conditions, and healthy individuals. By studying these samples, the researchers hope to find important clues that could help in diagnosing and treating MGUS in the future.

To be eligible for this study, participants need to be at least 45 years old and should not have any significant diseases that could affect the results. They also need to have enough blood and stool samples available for testing. Participants will be asked to provide these samples, and they will have the chance to contribute to important research that may lead to better understanding and care for MGUS. This study is currently recruiting, so if you or someone you know is interested, it might be a great opportunity to get involved in this important work.

Gender

ALL

Eligibility criteria

• (I) Inclusion Criteria:
• • 1. Age 45 years or older;
• • 2. Negative screening for monoclonal protein by MALDI-TOF MS;
• • 3. No significant diseases found upon medical examination, and confirmed not to have any diseases related to this study;
• • 4. Sufficient whole blood, plasma, serum, and stool samples available, and relevant case data can be provided.
• (II) Exclusion Criteria:
• • 1. History of intestinal tumors, irritable bowel syndrome, or inflammatory bowel disease, or diagnosed during hospitalization;
• • 2. Antibiotic treatment received in the past month; Presence of severe systemic diseases, including malignant tumors;
• • 3. Insufficient sample volume, or presence of severe hemolysis, lipemia, jaundice, or other unqualified sample conditions.